Shares of Immuron Ltd. (IMRN) are rallying over 76% in pre-market today, after the company announced that the Naval Medical Research Center or NMRC has received written guidance from the U.S. FDA in relation to the clinical development pathway of a new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli or ETEC infections.
from RTT - Before the Bell https://ift.tt/2OGNqFI
via IFTTT
No comments:
Post a Comment